Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania UPMC Montefiore Clinical and Translational Research Center, Pittsburgh, Pennsylvania